ELECTRONIC MONITORING OF COMPLIANCE WITH TB CHEMOTHERAPY

结核病化疗依从性的电子监测

• 批准号: 6143469
• 负责人: Leo Einck
• 金额: $ 30万
• 依托单位: SEQUELLA, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-29 至 2001-09-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6143469
• 关键词: antitubercular agents; bioengineering /biomedical engineering; biomedical equipment development; fluorescent dye /probe; microorganism disease chemotherapy; patient monitoring device; therapy compliance; tuberculosis

Noncompliance with medication is an age-old problem with serious consequences. Failure to take each dose of medicine prescribed often leads to treatment failure. In the case of infectious diseases, continuing transmission of the disease to others and the emergence of drug resistant strains are among the consequences that have public health implications. An elegant bioengineering solution to this problem is proposed, based upon a new and proprietary method of detecting fluorescence through the skin. By incorporating a fluorescent tracer compound into medication, ingestion of the tracer could be accurately documented, the time noted, and the data recorded for transmission to a remote monitoring site. Such a revolutionary device would be invaluable in many clinical situations. For example, it would help physicians ensure patient compliance with treatments that require strict adherence to a complex drug regimen, such as HIV disease therapy, asthma treatment, control of psychosis or drug addiction, immunosuppressive therapy for organ transplantation, and medical treatment of tuberculosis. Further, a compliance monitor would be very beneficial in the evaluation of results from clinical trials, allowing a distinction to be made between failure of the drug being tested and lack of patient compliance. PROPOSED COMMERCIAL APPLICATION: The long-term goal of this project is the commercial development of a wristwatch-like device that could log and transmit information documenting compliance, while being as convenient and satisfactory to the patient as possible.

不遵守药物治疗是一个长期存在的问题，会带来严重后果。未能按规定服用每剂药物通常会导致治疗失败。就传染病而言，疾病的持续传播和耐药菌株的出现是对公共卫生产生影响的后果之一。基于一种通过皮肤检测荧光的新的专有方法，针对这个问题提出了一种优雅的生物工程解决方案。通过将荧光示踪剂化合物掺入药物中，可以准确记录示踪剂的摄入情况、记录时间并记录数据以传输到远程监控站点。这种革命性的设备在许多临床情况下将具有无价的价值。例如，它将帮助医生确保患者遵守需要严格遵守复杂药物治疗方案的治疗，例如艾滋病毒疾病治疗、哮喘治疗、精神病或毒瘾的控制、器官移植的免疫抑制治疗以及结核病的药物治疗。 此外，依从性监测器对于评估临床试验结果非常有益，可以区分正在测试的药物失败和患者依从性缺乏。拟议的商业应用：该项目的长期目标是商业开发一款类似手表的设备，该设备可以记录和传输记录依从性的信息，同时尽可能方便和令患者满意。